# Cambrian Capital Partners

> Cambrian Capital Partners is a VC fund backing Fitness, Wellness and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Jul 2025
- Lead investor: 67%
- Last updated: Aug 2026
- Website: https://cambriancapital.ca/

Cambrian Capital Partners is a firm focused on providing off-market and creative investment solutions.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Fitness | 1 | 33% |
| Wellness | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Biotechnology | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Seed | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Journey Live | Journey is a simple meditation practice designed for the modern world, providing on-demand and live-streamed meditation courses.Journey was created to share meditation in a way that all people could relate to, wherever they are in life. It has created a simple yet powerful technique that could appeal to a large-scale audience, changing a lot ofpeople’s lives. It takes a step beyond meditation by introducing six simple yet powerful Life Lessons.Founded in 2015 by Stephen Sokoler, Journey Meditation is headquartered in New York. | $8M | Series A | Jul 25, 2025 |  |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $13.5M | Series A | May 01, 2025 |  |
| CND Life Sciences | CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $5M | Seed | Feb 01, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [HonorHealth](https://shizune.co/investors/profile/honorhealth) — VC Fund, 2 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together
- Gold Bench Capital — VC Fund, 1 deal together
- [HealthTech Capital](https://shizune.co/investors/profile/healthtech-capital) — VC Fund, 1 deal together
- [J-Impact](https://shizune.co/investors/profile/j-impact) — VC Fund, 1 deal together
- [J-Ventures](https://shizune.co/investors/profile/j-ventures-f370) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cambrian Capital Partners invest in?

Cambrian Capital Partners invests primarily in Fitness, Wellness and Health Care startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cambrian Capital Partners last invest?

The most recent investment recorded for Cambrian Capital Partners closed in Jul 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co